BiondVax rounds up $9.5M in IPO

BiondVax ($BVXV) raised $9.5 million in a Nasdaq IPO, pricing 1,910,000 shares at $5.01 each. The Israel-based company is working on a universal flu vaccine to protect against all strains of the virus, including seasonal strains and pandemics. CEO Ron Babecoff said the funds will allow BiondVax to "promote its clinical activities and speed it up while developing business-wise," Globes reported. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.